Ameritas Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.42M | Sell |
19,215
-402
| -2% | -$50.5K | 0.08% | 263 |
|
|
2025
Q1 | $2.17M | Sell |
19,617
-662
| -3% | -$73.2K | 0.07% | 289 |
|
|
2024
Q4 | $2.77M | Sell |
20,279
-437
| -2% | -$59.7K | 0.09% | 216 |
|
|
2024
Q3 | $2.39M | Sell |
20,716
-689
| -3% | -$79.4K | 0.08% | 270 |
|
|
2024
Q2 | $2.95M | Sell |
21,405
-538
| -2% | -$74.1K | 0.1% | 191 |
|
|
2024
Q1 | $3.03M | Buy |
21,943
+249
| +1% | +$34.3K | 0.1% | 194 |
|
|
2023
Q4 | $2.86M | Sell |
21,694
-207
| -0.9% | -$27.3K | 0.1% | 185 |
|
|
2023
Q3 | $2.46M | Sell |
21,901
-2,466
| -10% | -$277K | 0.1% | 200 |
|
|
2023
Q2 | $2.3M | Sell |
24,367
-223
| -0.9% | -$21K | 0.09% | 244 |
|
|
2023
Q1 | $2.49M | Sell |
24,590
-290
| -1% | -$29.4K | 0.1% | 212 |
|
|
2022
Q4 | $2.71M | Buy |
24,880
+284
| +1% | +$30.9K | 0.11% | 192 |
|
|
2022
Q3 | $2.61M | Sell |
24,596
-769
| -3% | -$81.7K | 0.12% | 156 |
|
|
2022
Q2 | $2.47M | Hold |
25,365
| – | – | 0.11% | 185 |
|
|
2022
Q1 | $2.38M | Hold |
25,365
| – | – | 0.09% | 256 |
|
|
2021
Q4 | $2.16M | Buy |
25,365
+294
| +1% | +$25K | 0.07% | 304 |
|
|
2021
Q3 | $2.41M | Sell |
25,071
-484
| -2% | -$46.4K | 0.09% | 243 |
|
|
2021
Q2 | $2.49M | Sell |
25,555
-245
| -0.9% | -$23.8K | 0.09% | 252 |
|
|
2021
Q1 | $2.51M | Buy |
+25,800
| New | +$2.51M | 0.1% | 230 |
|
|
2016
Q2 | – | Sell |
-6,662
| Closed | -$263K | – | 1189 |
|
|
2016
Q1 | $263K | Hold |
6,662
| – | – | 0.02% | 850 |
|
|
2015
Q4 | $377K | Buy |
6,662
+70
| +1% | +$3.96K | 0.03% | 694 |
|
|
2015
Q3 | $262K | Hold |
6,592
| – | – | 0.02% | 818 |
|
|
2015
Q2 | $315K | Sell |
6,592
-853
| -11% | -$40.8K | 0.02% | 791 |
|
|
2015
Q1 | $296K | Buy |
+7,445
| New | +$296K | 0.02% | 833 |
|